Earnings Call · Q3 FY2025·2025-02-13

Q3 25EPS +11.54%·Rev n/aQ2 25EPS -7.69%·Rev n/aQ1 25EPS +12.50%·Rev n/aQ4 24EPS +30.56%·Rev n/a⚠ consensus missing

Vistagen Therapeutics, Inc. VTGN

Mark McPartland — Vice President, Corporate Development & Investor Relations

Shawn Singh — Chief Executive Officer

Cindy Anderson — Chief Financial Officer

+4.2%1d on move date+4.2% vs SPY3d0.0%5d+2.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more VTGN calls or request research access.

More VTGN calls Browse calls Request research access